Title: Associate Professor
E-mail: [email protected]
Lattes: http://lattes.cnpq.br/6447371680399029
Bolsa produtividade CNPq: PQ 1D
Orcid:  ID 0000-0001-6194-5129 – https://orcid.org/0000-0001-6194-5129
Scopus: ID 7003547640 – https://www.scopus.com/authid/detail.uri?authorId=7003547640
Google scholar: ID A6Ig9qAAAAAJ – https://scholar.google.com.br/citations?user=A6Ig9qAAAAAJ&hl=pt-BR&oi=ao
Research ID:  D-1741-2012 – https://publons.com/researcher/1411812/eduardo-f-borba/

 

Line of research:

Autoimmune Rheumatological Diseases, with emphasis on Systemic Lupus Erythematosus, and their association with Atherosclerosis and Dyslipoproteinemias.

Summary

The objective of the line of research is to investigate clinical, laboratorial and immunological aspects of autoimmune diseases, Systemic Lupus Erythematosus in particular. One interesting focus of our studies is the important relationship between atherosclerosis and the inflammatory conditions of rheumatological diseases, which favor the early development of cardiovascular events in these patients. In fact, Autoimmune Rheumatological Diseases are extremely interesting models for deepening knowledge of the mechanisms of atherosclerosis installation and progression. Our main objective is to shed light on the basic aspects of this process, its inflammatory and cellular mechanisms, as well as to assess intervention measures to delay its installation and progression. In this way, we will expand knowledge of the physiopathogenic mechanisms in atherosclerosis, looking towards applying it to early diagnosis and therapy, as well as prevention.

Relevant articles:

  1. Muniz LF, Pereira RMR, Silva TF, Bonfá E, Borba EF. Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials. Arthritis Care Res (Hoboken). 2015 Sep;67(9):1255-1262. doi: 10.1002/acr.22593.
  2. Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012 Oct;21(11):1178-82. doi: 10.1177/0961203312450084.
  3. de Carvalho JF, Bonfá E, Borba EF. Systemic lupus erythematosus and “lúpus dyslipoproteinemia”. Autoimmun Rev. 2008 Jan;7(3):246-50. doi: 10.1016/j.autrev.2007.11.016.
  4. Borba EF, Bonfá E, Vinagre CG, Ramires JA, Maranhão RC. Chylomicron metabolismo is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000 May;43(5):1033-40.
  5. Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus:influence of disease, activity, and anticardiolipin antibodies. Lupus.1997;6(6):533-9.

 

PROJETOS ORIENTADOR/ LINHA

Linha 6. SISTEMA IMUNE E AUTOIMUNE
PROJETO EDUARDO BORBA: ETIOPATOGENESE, DIAGNÓSTICO, QUADRO CLÍNICO, COMORBIDADES E TRATAMENTO E PREVENÇÃO DE DOENÇAS OSTEOMETABÓLICAS
PROJETO EDUARDO BORBA: ETIOPATOGENESE, DIAGNÓSTICO, QUADRO CLÍNICO, COMORBIDADES E TRATAMENTO E PREVENÇÃO DE LUPUS ERITEMATOSO SISTÊMICO